NasdaqGM:ETON

Stock Analysis Report

Executive Summary

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.

Risks

  • Eton Pharmaceuticals has significant price volatility in the past 3 months.
  • Eton Pharmaceuticals is covered by less than 3 analysts.

Share Price & News

How has Eton Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.6%

NasdaqGM:ETON

2.3%

US Pharmaceuticals

2.9%

US Market


1 Year Return

n/a

NasdaqGM:ETON

-5.8%

US Pharmaceuticals

0.2%

US Market

No trading data on ETON.

No trading data on ETON.


Share holder returns

ETONIndustryMarket
7 Day1.6%2.3%2.9%
30 Day-7.9%-1.0%-2.3%
90 Day-31.1%-3.6%3.1%
1 Yearn/a-3.5%-5.8%2.4%0.2%
3 Yearn/a11.3%3.7%41.7%32.4%
5 Yearn/a23.3%10.3%55.1%37.9%

Price Volatility Vs. Market

How volatile is Eton Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Eton Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

6.12x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Eton Pharmaceuticals to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Eton Pharmaceuticals to establish if it is available at substantial discount.


Price Based on Earnings

Eton Pharmaceuticals is loss making, we can't compare its value to the US Pharmaceuticals industry average.

Eton Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Eton Pharmaceuticals, we can't assess if its growth is good value.


Price Based on Value of Assets

Eton Pharmaceuticals is overvalued based on assets compared to the US Pharmaceuticals industry average.


Next Steps

Future Growth

How is Eton Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

66.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Eton Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.

Eton Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.

Eton Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.

Unable to compare Eton Pharmaceuticals's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Eton Pharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Eton Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Eton Pharmaceuticals performed over the past 5 years?

-144.0%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Eton Pharmaceuticals does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.

Unable to compare Eton Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Eton Pharmaceuticals's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Eton Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Eton Pharmaceuticals has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Eton Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Eton Pharmaceuticals's financial position?


Financial Position Analysis

Eton Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Eton Pharmaceuticals's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Eton Pharmaceuticals has no debt.

Eton Pharmaceuticals has not taken on any debt in the past 5 years.


Balance Sheet

Low level of unsold assets.

Eton Pharmaceuticals has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Eton Pharmaceuticals has less than a year of cash runway based on current free cash flow.

Eton Pharmaceuticals has less than a year of cash runway if free cash flow continues to grow at historical rates of 49.4% each year.


Next Steps

Dividend

What is Eton Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Eton Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Eton Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Eton Pharmaceuticals has not reported any payouts.

Unable to verify if Eton Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Eton Pharmaceuticals has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Eton Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

2.2yrs

Average board tenure


CEO

Sean Brynjelsen (47yo)

2.2yrs

Tenure

US$493,022

Compensation

Mr. Sean E. Brynjelsen has been the Chief Executive Officer at Eton Pharmaceuticals, Inc. since June 23, 2017 and serves as President and Director since June 2017. Mr. Brynjelsen served as Executive Vice P ...


CEO Compensation Analysis

Sean's remuneration is about average for companies of similar size in United States of America.

Sean's compensation has been consistent with company performance over the past year, both up more than 20%.


Board Age and Tenure

2.2yrs

Average Tenure

61yo

Average Age

The average tenure for the Eton Pharmaceuticals board of directors is less than 3 years, this suggests a new board.


Insider Trading

More shares have been bought than sold by Eton Pharmaceuticals individual insiders in the past 3 months.


Recent Insider Transactions

BuyUS$30,75013 Aug 19
Sean Brynjelsen
EntityIndividual
Role
Chief Executive Officer
President
Shares5,000
Max PriceUS$6.15
BuyUS$21,37012 Aug 19
Charles Casamento
EntityIndividual
Role
Member of the Board of Directors
Director
Shares3,500
Max PriceUS$6.11
BuyUS$79,32622 May 19
Sean Brynjelsen
EntityIndividual
Role
Chief Executive Officer
President
Shares10,000
Max PriceUS$7.96
BuyUS$30,00016 Nov 18
Charles Casamento
EntityIndividual
Role
Member of the Board of Directors
Director
Shares5,000
Max PriceUS$6.00
BuyUS$60,00016 Nov 18
Sean Brynjelsen
EntityIndividual
Role
Chief Executive Officer
President
Shares10,000
Max PriceUS$6.00
BuyUS$30,00016 Nov 18
Paul Maier
EntityIndividual
Role
Member of the Board of Directors
Director
Shares5,000
Max PriceUS$6.00
BuyUS$30,00016 Nov 18
Norbert Riedel
EntityIndividual
Role
Chairman of the Board
Chairman
Shares5,000
Max PriceUS$6.00
BuyUS$30,00016 Nov 18
W. Troutman
EntityIndividual
Role
Chief Financial Officer
CFO, Treasurer & Secretary
Shares5,000
Max PriceUS$6.00
BuyUS$60,00016 Nov 18
Mark Baum
EntityIndividual
Role
Member of the Board of Directors
Director
Shares10,000
Max PriceUS$6.00

Ownership Breakdown


Management Team

  • Sean Brynjelsen (47yo)

    President

    • Tenure: 2.2yrs
    • Compensation: US$493.02k
  • W. Troutman (64yo)

    CFO, Treasurer & Secretary

    • Tenure: 2.1yrs
    • Compensation: US$296.55k
  • Bharathi Devarakonda

    Senior Vice President of Regulatory Affairs & Product Development

    • Tenure: 0.0yrs
  • Scott Grossenbach

    Vice President of Sales & Marketing

    • Tenure: 0.0yrs

Board Members

  • Paul Maier (71yo)

    Director

    • Tenure: 1.9yrs
    • Compensation: US$125.00k
  • Chuck Casamento (74yo)

    Director

    • Tenure: 2.2yrs
    • Compensation: US$125.00k
  • Norbert Riedel (61yo)

    Chairman

    • Tenure: 0.9yrs
    • Compensation: US$125.00k
  • Mark Baum (46yo)

    Director

    • Tenure: 2.3yrs
    • Compensation: US$125.00k
  • Sean Brynjelsen (47yo)

    President

    • Tenure: 2.2yrs
    • Compensation: US$493.02k

Company Information

Eton Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Eton Pharmaceuticals, Inc.
  • Ticker: ETON
  • Exchange: NasdaqGM
  • Founded: 2017
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$102.138m
  • Shares outstanding: 17.76m
  • Website: https://www.etonpharma.com

Number of Employees


Location

  • Eton Pharmaceuticals, Inc.
  • 21925 West Field Parkway
  • Suite 235
  • Deer Park
  • Illinois
  • 60010
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ETONNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDNov 2018

Biography

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. It primarily focuses on liquid products, including injectable, oral liquid ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/22 01:23
End of Day Share Price2019/08/21 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.